Alternatives to Carvedilol for Hypertension and Heart Failure

Introduction to Alternatives

The American College of Cardiology recommends metoprolol succinate, bisoprolol, or nebivolol as preferred beta-blockers with proven mortality benefit in heart failure, while for hypertension alone, any first-line antihypertensive class is appropriate 1, 2

Metoprolol succinate (extended-release) 50-200 mg once daily is proven to reduce mortality in the MERIT-HF trial, with a strength of evidence based on randomized controlled trials 1, 3
Bisoprolol 2.5-10 mg once daily demonstrated a 32% reduction in all-cause mortality and 44% reduction in sudden death in the CIBIS-II trial, providing high-quality evidence for its use 1, 3
Nebivolol 5-40 mg once daily, a β1-selective blocker with vasodilating properties, significantly reduced mortality/cardiovascular hospitalizations in elderly patients (≥70 years) in the SENIORS trial, offering moderate to high strength of evidence 1, 3

ACE inhibitors or ARBs are foundational therapy for HFrEF and also lower blood pressure effectively, with examples including lisinopril, enalapril, losartan, and valsartan, based on strong evidence from clinical guidelines 1, 2
Mineralocorticoid receptor antagonists, such as spironolactone 25-100 mg once daily and eplerenone 50-100 mg once or twice daily, reduced mortality by 30% in the RALES trial and by 15% post-MI in the EPHESUS trial, respectively, providing high-quality evidence for their use 3
Thiazide-type diuretics, such as chlorthalidone and hydrochlorothiazide, are first-line for hypertension and effective in reducing HF incidence, with a strength of evidence based on clinical trials and guidelines 1, 2

The 2017 ACC/AHA guidelines recommend ACE inhibitors, ARBs, thiazide-type diuretics, and calcium channel blockers as first-line options for hypertension management without heart failure, based on strong evidence from clinical trials 1, 2

For patients with recent MI and left ventricular dysfunction (ejection fraction ≤40%), alternative beta-blockers (metoprolol succinate, bisoprolol) are appropriate substitutes, with a strength of evidence based on randomized controlled trials 1, 3

The target systolic BP is <130 mmHg for patients with HFrEF, though successful trials achieved 110-130 mmHg, based on moderate to high strength of evidence from clinical trials 2
For general hypertension, the target is <130/80 mmHg per 2017 ACC/AHA guidelines, with a strength of evidence based on strong clinical evidence 1, 2

The evidence supports combination therapy with ACE inhibitor/ARB + thiazide diuretic as the most common and effective combination, with a strength of evidence based on clinical trials and guidelines 1
For African American patients with advanced HF (NYHA class III-IV), adding hydralazine 100-200 mg plus isosorbide dinitrate to standard therapy reduced mortality by 40% in the A-HeFT trial, providing high-quality evidence for this approach 3